Genomtec SA (4VI) Stock Statistics & Valuation Metrics

Genomtec SA has a market cap or net worth of €18.54M. The enterprise value is €73.97M.

Genomtec SA has 15,064,634 shares outstanding. The number of shares has decreased by -2.65% in one year.

Genomtec SA’s return on equity (ROE) is -1.47 and return on invested capital (ROIC) is -85.60%.

The current PE Ratio of Genomtec SA is ―. Genomtec SA’s PEG ratio is -0.69.

In the last 12 months, Genomtec SA had revenue of 1.00K and earned -11.21M in profits. Earnings per share was -0.84.

In the last 12 months, operating cash flow was -7.80M and capital expenditures -117.00K, giving a free cash flow of -7.92M billion.

Genomtec SA pays an annual dividend of ―, resulting in a dividend yield of ―

Genomtec SA upcoming earnings date is May 5, 2026, TBA (Confirmed).

Genomtec SA as a current ratio of 1.55, with Debt / Equity ratio of 20.58%

In the past 12 months, Genomtec SA has paid 20.00K in taxes.

Genomtec SA EV to EBITDA ratio is -11.57, with an EV/FCF ratio of -14.90.

Genomtec SA has €7.40M in cash and marketable securities with €2.13M in debt, giving a net cash position of €5.27M billion.

Gross margin is -62713.33%, with operating margin of -1105500.00%, and net profit margin of -1120800.00%.

The average price target for Genomtec SA is ―, which is 11.43% higher than the current price. The consensus rating is ―